JAGX Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Jaguar Health Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerJAGX

Market Cap1.9M

Cash RunwayRunway < 6 months

Next Catalystn/a

Public Research Snapshot

Jaguar Health Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Crofelemer (tablet formulation) (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Crofelemer (tablet formulation)	n/a	n/a	Phase 3	Public pipeline row
Crofelemer (liquid formulation)	toxicity studies	n/a	Preclinical	Public pipeline row
NP-300	symptomatic relief of diarrhea from cholera	n/a	n/a	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
No public trial rows are loaded yet.

Scientific Context

literature_publication | Occurrence of microplastics in fishing cat (Prionailurus viverrinus) scat: Hidden threats to wetland ecosystems of Thailand.
literature_publication | Development of a face-validated conceptual model structure for economic evaluation in phenylketonuria, through expert elicitation.
literature_publication | Interacting effects of human presence and landscape modification on birds and mammals.
literature_publication | AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41.
literature_publication | Parent-Reported Outcome Measures for Individuals with Fragile X Syndrome: Clinically Meaningful Change Thresholds.

Want the full JAGX research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.